Evaluation of haloperidol decanoate initiation dosing in inpatients with serious mental illness [0.03%]
评估住院严重精神疾病患者的氟哌啶醇癸酸酯启动剂量
Grace Lim,Albert Ngo,Tien Cam Le et al.
Grace Lim et al.
Introduction: Manufacturer labeling for haloperidol decanoate recommends an initial dose of 10 to 20 times the daily oral dose; however, significant heterogeneity in dosing practices exists. The purpose of this medication...
Secretagogue laxatives as a potential strategy to overcome adherence barriers to over-the-counter treatment for clozapine-induced constipation [0.03%]
秘鲁酸盐通便药作为克服氯氮平引起的便秘的非处方治疗依从性障碍的潜在策略
Jonathan G Leung,Matej Markota,Xiao Jing Wang
Jonathan G Leung
Introduction: Clozapine-induced constipation may occur in at least 60% of patients, with first-line options typically involving polyethylene glycol or sennosides. However, there may be adherence barriers to an over-the-co...
Foster care psychotropic prescribing regulations are complex and insufficient [0.03%]
收养心理治疗开处方的条例复杂且不足
Danielle L Stutzman,Mary Accomando,Matthew Dick et al.
Danielle L Stutzman et al.
Introduction: Federal and state policymakers, accreditation organizations, and mental health agencies developed standards for evidence-based use of psychotropic medications among youth in foster care. Despite these effort...
The role of board-certified psychiatric pharmacists in United States foster care: Opportunities to optimize psychotropic medication use [0.03%]
美国认证精神病药物临床药师在孤儿院中的角色：促进精神病药物使用的优化措施的机会评估
Danielle L Stutzman,Andreea Temelie,Mary Accomando et al.
Danielle L Stutzman et al.
Polypharmacy, gaps in transitions of care, and inconsistent medication monitoring contribute to inappropriate psychotropic prescribing among youth in foster care. Additionally, foster care psychotropic prescribing regulations are complex an...
Reply to: The efficacy and safety of antidepressants as alternative treatment of attention-deficit/hyperactivity disorder in pediatric populations [0.03%]
有关抗抑郁药作为儿童注意缺陷多动障碍替代治疗有效性和安全性的来信答复
Joshua Caballero,Julio Chavez
Joshua Caballero
High-dose olanzapine versus standard-dose olanzapine: Effect on all-cause readmission rates in adult psychiatric patients [0.03%]
高剂量奥氮平与常规剂量奥氮平对精神病患者再住院率的影响：一项开放性随机对照试验
Teressa Benbarka,Andrew Williams
Teressa Benbarka
Introduction: Olanzapine doses in adults with treatment-resistant schizophrenia or treatment-resistant schizoaffective disorder have been compared in a few open-label trials, with higher doses associated with increased sy...
Pharmacotherapy for pediatric and adolescent agitation in an inpatient behavioral health unit [0.03%]
住院行为健康单元中的儿科和青少年烦躁的药物治疗
Michelle Yang,Christine M Rarrick,Clint Ross
Michelle Yang
Introduction: Pro re nata (PRN) medications can be administered for the treatment of agitation. Evidence-based recommendations for the pharmacologic treatment of agitation in children and adolescents admitted to a behavio...
Utilization of adjunctive anti-seizure medications to facilitate chronic benzodiazepine discontinuation [0.03%]
辅助抗癫痫药物在慢性苯二氮卓类药物戒断中的应用
Michael R Dueno,Gavin T Howington,Melody Ryan
Michael R Dueno
Introduction: When discontinuing benzodiazepines, treating withdrawal symptoms can be challenging. Some anti-seizure medications (ASM) may mitigate withdrawal symptoms. This article reviews the literature regarding adjunc...
The relationship between vitamin B9 (folate) supplementation and suicidality: a scoping review [0.03%]
叶酸补充与自杀行为的相关性：系统综述
Chris Noel,Nick Lombardi,Michelle Price et al.
Chris Noel et al.
Introduction: Emerging real-world evidence suggests that folate supplementation may reduce suicidal ideation and behavior. We conducted a scoping review to evaluate current hypothesis-testing literature on folate suppleme...
Hyperammonemia associated with low doses and concentrations of valproic acid in older adults with neurocognitive disorder [0.03%]
与神经认知障碍老年患者低剂量和浓度的丙戊酸钠相关的血氨升高
Sunni Coyne,Aparna Das
Sunni Coyne
Hyperammonemia is an idiosyncratic adverse effect associated with valproic acid (VPA). We report 2 patients with neurocognitive disorder who were prescribed low doses of VPA for neuropsychiatric symptoms associated with neurocognitive disor...